Mizuho Increases Gilead Sciences (NASDAQ:GILD) Price Target to $170.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by stock analysts at Mizuho from $140.00 to $170.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 11.30% from the company’s current price.

A number of other research firms have also recently weighed in on GILD. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Wells Fargo & Company lifted their price target on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Morgan Stanley upped their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Needham & Company LLC lifted their price target on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $154.21.

Gilead Sciences Stock Performance

Shares of GILD opened at $152.74 on Wednesday. The firm has a market cap of $189.50 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 2.06 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average is $132.29 and its two-hundred day moving average is $123.18. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares in the company, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 319,891 shares of company stock worth $45,091,556. 0.27% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $26,000. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Finally, Corundum Trust Company INC bought a new position in Gilead Sciences during the 3rd quarter worth approximately $26,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target to $170 and kept a Buy rating, signaling meaningful analyst upside vs. the recent price and supporting potential buying interest. Rothschild PT Raise
• Positive Sentiment: Gilead’s reported Q4 beat and reiterated FY26 EPS guidance, coupled with reported progress in the HIV franchise and a Yescarta label shift, bolster the investment thesis of steady HIV cash flows plus potential CAR‑T upside. HIV & Yescarta Article
• Positive Sentiment: Gilead recently raised its quarterly dividend to $0.82 (from $0.79), increasing yield and returning more cash to shareholders — supportive for income-focused investors. MarketBeat Summary
• Neutral Sentiment: Maxim Group reiterated a Hold rating, noting HIV growth may be largely priced in and diversification still looks limited — a caution that tempers near-term upside. TipRanks / Hold Rating
• Neutral Sentiment: Analyst Q&A and earnings‑call coverage highlight pipeline timing, margins and guidance drivers — useful context for positioning but mixed in directional impact. Earnings Call Questions
• Neutral Sentiment: Retrospective pieces on multi‑year returns (e.g., Benzinga) are informative for retail holders but unlikely to move price materially. Benzinga Performance Piece
• Negative Sentiment: CFO Andrew D. Dickinson sold 3,000 shares at about $154.43 (Form 4 filing). Even routine insider sales can sap near‑term sentiment, particularly alongside other insider moves. CFO Form 4
• Negative Sentiment: Significant insider sale by Johanna Mercier: 28,000 shares sold at ~ $154.44 (an ~18.9% reduction in her holding). That larger leadership sale is likely the primary driver of today’s negative sentiment and selling pressure. Mercier Form 4

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.